Typhoid Fever: Clinical Features, Diagnosis and Management in India
Clinical Features
Typhoid fever presents with insidious onset of sustained fever over 3-7 days, accompanied by headache, malaise, anorexia, relative bradycardia, and either constipation or diarrhea 1, 2. The fever typically follows a stepladder pattern, though many mild and atypical infections occur 1, 3.
Key clinical features to identify:
- Fever duration: Usually 7-15 days at presentation in Indian settings 4
- Gastrointestinal symptoms: Abdominal pain, vomiting, anorexia
- Hepatomegaly: Present in approximately 57% of cases with nalidixic acid-resistant strains 4
- Relative bradycardia: Pulse-temperature dissociation
- Nonproductive cough: Common respiratory manifestation 1
- Elevated liver enzymes: AST levels typically 121 IU/L or higher in resistant strains 4
Life-threatening complications emerge in the second week of untreated illness, including intestinal perforation, hemorrhage, and encephalopathy 2.
Diagnosis
Blood Culture: The Reference Standard
Blood culture remains the gold standard for diagnosis despite low sensitivity (9.81% in Indian studies) 5. Sensitivity is highest in the first week of illness before antibiotic exposure 5. The major limitation is that most Indian patients receive antibiotics before presentation, significantly reducing culture yield.
Rapid Diagnostic Tests
For practical diagnosis in India where blood culture facilities are limited:
Typhifast IgM demonstrates the best performance with 97% sensitivity and 85% specificity 3. This rapid serological test detects IgM antibodies to the 50kD outer membrane protein of Salmonella and provides results within 1 hour 5.
- Widal test: Shows 65% sensitivity and 90% specificity, with significant detection in the second week 5. However, interpretation is challenging due to endemic exposure and prior vaccination.
- Enterocheck WB: Lower performance (69% sensitivity, 63% specificity) 3
Diagnostic Algorithm for India
- First week of fever: Obtain blood culture before antibiotics if possible
- After first week or prior antibiotic use: Use Typhifast IgM for rapid diagnosis
- Combination approach: Serial combination of blood culture and Typhifast IgM achieves 85% sensitivity and 85% specificity 3
Critical caveat: Serologic evidence alone is insufficient for confirmation per CDC guidelines 1, but in resource-limited Indian settings with high pre-test probability, rapid tests provide practical diagnostic value.
Management
Antibiotic Selection Based on Resistance Patterns
The Indian resistance landscape has fundamentally changed: azithromycin or ceftriaxone should be first-line therapy, NOT fluoroquinolones 6, 2.
Current Indian Resistance Data (2017-2020):
From the largest multicenter Indian surveillance study 6:
- Multidrug resistance (MDR): Only 2% of S. Typhi (declining trend)
- Nalidixic acid resistance: 51% of isolates 7
- Ciprofloxacin non-susceptibility: 98% of isolates 6
- Ciprofloxacin resistance (MIC >0.5 µg/mL): 37% of S. Typhi 6
- Ceftriaxone susceptibility: 100% retained 6
- Azithromycin susceptibility: 99.9% 6
Treatment Algorithm for India
First-line therapy:
Azithromycin: 10-14 days (preferred for uncomplicated cases)
Ceftriaxone: 10-14 days (preferred for severe cases or complications)
Second-line therapy (if first-line fails):
- Switch between azithromycin and ceftriaxone based on initial choice
Avoid fluoroquinolones as first-line therapy in India due to:
- 98% non-susceptibility rates 6
- Nalidixic acid-resistant S. Typhi (NARST) causes longer fever duration (median 10 vs. 4 days), higher complication rates, and clinical failure despite in-vitro "susceptibility" 4
- All 11 patients with complications in one Indian study had NARST infections 4
Special Considerations for India
Duration of prior antibiotic use strongly correlates with prolonged illness (r=0.53, p=0.000) 4, emphasizing the importance of:
- Avoiding empirical fluoroquinolone use for undifferentiated fever
- Early appropriate antibiotic selection
- Completing full treatment courses
Beta-lactam/beta-lactamase inhibitor combinations show potent in-vitro activity 6 and may represent future alternatives, though clinical trial data are needed.
Monitoring and Complications
Monitor for:
- Fever clearance: Should occur within 3-5 days with appropriate therapy
- Hepatotoxicity: Check liver enzymes if hepatomegaly present
- Complications: Intestinal perforation, hemorrhage (second week risk)
- Relapse: Occurs in approximately 5-10% of cases
Clinical failure indicators: Persistent fever beyond 5 days of appropriate therapy, worsening symptoms, or development of complications warrant treatment modification 4.
Prevention
Typhoid Vi-conjugate vaccines are now available and recommended for endemic areas in India 2. Vaccination combined with water, sanitation, and hygiene measures form the cornerstone of prevention 2.